1. 65PDHigh tumor mutational burden (TMB) and PD-L1 have similar predictive utility in 2L+ NSCLC patients (pts) treated with anti-PD-L1 and anti-CTLA-4. (23rd October 2018) Authors: Higgs, B W; Morehouse, C A; Brohawn, P Z; Sridhar, S; Raja, R; Gao, G; Englert, J; Ranade, K Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗